title: [BDNF secretion in human mesenchymal stem cells isolated from bone marrow, endometrium and adipose tissue].
abstract: The ability of mesenchymal stem cells (MSCs) to differentiate into neuronal lineage determines the potential of these cells as a substrate for a cell replacement therapy. In this paper we compare the neurogenic potential of MSCs isolated from bone marrow (BMSC), subcutaneous adipose tissue (AD MSC) and menstrual blood (eMSC). It was found that the native eMCSs, BMSCs and AD MSCs express neuronal marker β-III-tubulin with a frequency of 90, 50 and 14%, respectively. We also showned that eMSCs have a high endogenous level of brain-derived neurotrophic factor (BDNF), whereas the BMSCs and the AD MSCs are characterized by low basal BDNF levels. As induction of neuronal differentiation in the studied MSCs using differentiation medium containing B27 and N2 supplements, 5-azacytidine, retinoic acid, IBMX and dbcAMF caused changes in the cells morphology, the increased expression of β-III-tubulin, and the appearance of neuronal markers GFAP, NF-H, NeuN and MAP2. BDNF secretion during differentiation was significantly enhanced in the BMSCs and decreased in the eMSCs cultures. However, no correlation between the basal and induced levels of the neuronal markers expression and BDNF secretion in the studied MSCs has been established.
authors.forename: V I
authors.initials: VI
authors.lastname: Zemel'ko
authors.forename: I V
authors.initials: IV
authors.lastname: Kozhukharova
authors.forename: Z V
authors.initials: ZV
authors.lastname: Kovaleva
authors.forename: A P
authors.initials: AP
authors.lastname: Domnina
authors.forename: N A
authors.initials: NA
authors.lastname: Pugovkina
authors.forename: I I
authors.initials: II
authors.lastname: Fridlianskaia
authors.forename: M V
authors.initials: MV
authors.lastname: Puzanov
authors.forename: S V
authors.initials: SV
authors.lastname: Anisimov
authors.forename: T M
authors.initials: TM
authors.lastname: Grinchuk
authors.forename: N N
authors.initials: NN
authors.lastname: Nikol'skiĭ
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D034961:Antigens, Nuclear / Q000235:genetics / Q000378:metabolism; D001374:Azacitidine / Q000494:pharmacology; D015415:Biomarkers / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D004717:Endometrium / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D015870:Gene Expression; D005904:Glial Fibrillary Acidic Protein / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008598:Menstruation; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D016900:Neurofilament Proteins / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D050151:Subcutaneous Fat / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology; D014404:Tubulin / Q000235:genetics / Q000378:metabolism
chemical_list: D034961:Antigens, Nuclear; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D005904:Glial Fibrillary Acidic Protein; C489788:MAP2 protein, human; D008869:Microtubule-Associated Proteins; D009419:Nerve Tissue Proteins; D016900:Neurofilament Proteins; C498585:TUBB3 protein, human; D014404:Tubulin; C506808:neuronal nuclear antigen NeuN, human; C051774:neurofilament protein H; D014212:Tretinoin; D003994:Bucladesine; C579455:BDNF protein, human; D001374:Azacitidine; D015056:1-Methyl-3-isobutylxanthine